GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,

Debate over the risks and benefits of the population weight loss drugs like Ozempic, Wegovy, and Zepbound finally came to an end after a new landmark study.According to Global News, a new observational study published in the journal

Several years ago, a little-known drug named Ozempic – previously used only to treat diabetes – emerged as a promising new drug for weight management. The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists,

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss.

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight.In report published in Nature Medicine,

According to a Nature Medicine study, weight loss drugs can be highly effective in improving several unexpected health conditions. Dr. Anthony Harris discusses why he believes the FDA should update the drug's label to include other conditions it can treat.

Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and other medications like it have a host of other potential health benefits beyond obesity,